Navigation Links
Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
Date:11/10/2011

PALO ALTO, Calif., Nov. 10, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today two clinical presentations at the 53rd Annual Meeting of the American Society of Hematology in San Diego, California. Details of the presentations are as follows:

  • Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS); Azra Raza, MD; Naomi Galili, PhD; Deborah Mulford, MD; Scott E. Smith, MD, PhD, FACP; Gail Brown, MD; Lisa Meng, PhD; David P. Steensma, MD; Roger M Lyons, MD; Ralph Boccia, MD; Mikkael A. Sekeres, MD, MS; Guillermo Garcia-Manero, MD; and Ruben A. Mesa, MD
    • Abstract #2778 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM -8:00 PM; San Diego Convention Center, Hall GH
  • Gene Expression Studies May Identify Lower Risk Myelodysplastic Syndrome Patients Likely to Respond to Therapy with Ezatiostat Hydrochloride (TLK199); Naomi Galili, Ph.D.; Pablo Tamayo, PhD; Olga B Botvinnik; Jill P Mesirov, PhD; Jennifer Zikria, MD; Gail Brown, MD and Azra Raza, MD
    • Abstract #2779 – Myelodysplastic Syndromes: Poster II; Sunday, December 11, 2011, 6:00 PM - 8:00 PM; San Diego Convention Center, Hall GH

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Related medicine technology :

1. Telik Announces Third Quarter 2011 Financial Results
2. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
3. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
5. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
6. Telik Announces First Quarter 2011 Financial Results
7. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
8. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
9. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
10. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
11. Telik Announces Presentation at American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... giving viewers the lowdown on sciatica in a new episode of "Success Files," ... on current events and innovation and investigates each subject in-depth with passion and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):